Subscribe to thousands of academic journals for just $40/month
Read and share the articles you need for your research, all in one place.

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

Details

Publisher
Springer-Verlag
Copyright
Copyright © 2003 by Springer-Verlag
Subject
Medicine
ISSN
0344-5704
eISSN
1432-0843
D.O.I.
10.1007/s00280-003-0696-7
Publisher site
See Article on Publisher Site
Expand Tray Hide Tray
Loading next page...

End of preview. The entire article is 7 pages. Rent for Free

You're using the new DeepDyve HTML5 Viewer. Having issues? Try Classic Viewer
 
/lp/springer-journals/a-phase-ii-study-of-intravenous-exatecan-mesylate-dx-8951f-d18sQAEwZW